Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-859 · 1 trial · 1 indication
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.
Cmax of ABBV-859
Beta of ABBV-859
t1/2 of ABBV-859
AUCt of ABBV-859
AUCinf of ABBV-859
CL/F of ABBV-859
Incidence and concentration of anti-drug antibodies.
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose A, or the Placebo equivalent, on Study Day 1 |
| Group 2 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose B, or the Placebo equivalent, on Study Day 1 |
| Group 3 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose C, or the Placebo equivalent, on Study Day 1 |
| Group 4 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose D, or the Placebo equivalent, on Study Day 1 |
| Group 5 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose E, or the Placebo equivalent, on Study Day 1 |
| Group 6 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose F, or the Placebo equivalent, on Study Day 1 |
| Group 7 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose G, or the Placebo equivalent, on Study Day 1 |
| Group 8 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose H, or the Placebo equivalent, on Study Day 1 |
| Name | Type | Description |
|---|---|---|
| ABBV-859 | DRUG | Oral Tablet |
| Placebo for ABBV-859 | DRUG | Oral Tablet |
Inclusion Criteria: * Participants must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. * Body Mass Index (BMI) is \>= 18.0 to \<= 32 kg/m2 after...
ABBV-859 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development to assess its safety, tolerability, and how it moves through the body. It is not approved for any condition and is being evaluated in a clinical trial setting.
ABBV-859 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and pharmacokinetics in healthy adult participants.
ABBV-859 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to study the safety, tolerability, and how single ascending doses of the drug move through the body.
ABBV-859 is being studied in one active Phase 1 clinical trial, identified as NCT07736638. This randomized, double-blind, controlled study is recruiting 64 healthy adult participants in the United States to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of the drug.
ABBV-859 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is designed to assess its safety and how it is processed by the body in healthy volunteers, which is an early stage of the drug development process.